Novo Nordisk

A text-to-SQL agent built by Novo's Rare Disease Insights & Analytics team that answers plain-language business questions from claims and prescription data.

Partners: Dataiku

A generative AI chatbot built on Dataiku that answers field sales questions about incentive-compensation rules.

Partners: Dataiku

A Dataiku-built generative AI tool that assesses scientific literature for relevance and gaps for medical affairs.

Partners: Dataiku

An enterprise rollout of Microsoft Copilot starting in early 2024 that reached about 20,000 employees. Users saved about 2.17 hours a week on average.

Partners: Microsoft

Novo runs its own internal ChatGPT and other generative AI tools to raise employee productivity. It listed them in its 2024 Capital Markets Day data-science deck.

A collaboration to test Anthropic's Claude Science on chosen R&D problems and use Anthropic models for AI-assisted software engineering.

Partners: Anthropic

A collaboration with NVIDIA to build custom AI models and agents for early research and clinical development on the Gefion AI supercomputer.

Partners: NVIDIA, Danish Centre for AI Innovation (DCAI)

Novo worked with Columbia University and AWS inside the OpenFold consortium to train the OpenFold3 protein-structure model.

Partners: AWS, Columbia University, OpenFold Consortium

An expanded collaboration using Valo's human-data and AI platform to discover up to 20 drug programs in obesity, type 2 diabetes and cardiovascular disease.

Partners: Valo Health

Novo named AWS its preferred cloud and strategic AI partner. It plans to use Amazon Bio Discovery for target and therapy design and Bedrock AgentCore for AI agents across operations.

Partners: AWS

Novo's global business services head said AI now drafts regulatory documents, analyzes safety data and supports commercial analytics, shortening the path from last patient visit to filing.

A partnership to apply OpenAI's models from drug discovery to commercial operations and to upskill Novo's workforce.

Partners: OpenAI

A platform on Databricks for secondary use of completed clinical-trial data. It gives scientists and analysts access to billions of trial data points.

Partners: Databricks

Novo will use H1's AI-powered data to improve trial design, site selection and enrollment. H1 also takes rights to advance Novo's in-house StudyHub platform.

Partners: H1

A custom AI agent that helps researchers test clinical hypotheses against proprietary trial data using AI-generated analysis. It is live internally with broader rollout under way.

Partners: Microsoft

Novo uses AI to find subpopulations, improve trial design and site selection, and forecast outcomes, drawing on harmonized data from about 1,600 trials.

An interpretable machine-learning method developed with Microsoft on UK Biobank data to predict atherosclerosis risk and flag new targets and biomarkers.

Partners: Microsoft

Conversational AI analytics over a governed Snowflake commercial data layer that gives US field leaders faster answers on weekly performance changes.

Partners: Tellius, Snowflake

A self-service platform that lets employees build their own chatbots on Amazon Bedrock foundation models. AWS reports about 2,500 chatbots and 25,000 employees using it.

Partners: AWS, Cloud2 Oy

An in-house generative AI documentation platform built on Claude via Amazon Bedrock with MongoDB Atlas for drafting regulatory documents such as clinical study reports. Anthropic reports large time savings.

Partners: Anthropic, AWS, MongoDB

Novo combined AI with high-throughput experiments to assess one billion virtual molecules. The work led to a selective amylin compound.

Machine-learning computer vision on production lines for tasks such as counting cartridges and spotting anomalies on agar plates, with models deployed to edge devices.

Partners: AWS